Last reviewed · How we verify
PD-1 and ACE2 Knockout T Cells
At a glance
| Generic name | PD-1 and ACE2 Knockout T Cells |
|---|---|
| Sponsor | Mahmoud Ramadan mohamed Elkazzaz |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- CRISPR/Cas9-modified Human T Cell ( PD-1and ACE2 Knockout Engineered T Cells ) for Inducing Long-term Immunity in COVID-19 Patients (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- PD-1 and ACE2 Knockout T Cells CI brief — competitive landscape report
- PD-1 and ACE2 Knockout T Cells updates RSS · CI watch RSS
- Mahmoud Ramadan mohamed Elkazzaz portfolio CI